Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e., ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies' board, in its meeting on 6th May 2025, approved a valuation report obtained from a registered valuer (Mr. Manish Santosh Buchasia) in connection with a proposed preferential issue of securities. The 'Relevant Date' for determining the issue price under SEBI ICDR Regulations has been fixed as Friday, 2nd May 2025. The board also decided to convene an Extra-Ordinary General Meeting (EGM) on Tuesday, 3rd June 2025 via video conferencing to seek shareholder approval for the preferential issue. The company has not yet disclosed the size of the issue, the price, or the identity of the proposed allottees in this filing.
This is a preliminary step toward a preferential allotment — the actual terms (size, price, investors) are expected in subsequent filings and the EGM notice. Existing shareholders should watch for dilution impact once these details are shared ahead of the 3rd June EGM.